Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4010 + Nivolumab + Chemotherapy in Advanced Non-Squamous NSCLC
NCT03353675Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Jan 2018
- Primary completion
- Nov 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of TG4010 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Transgene SA. Started Jan 2018; status: completed.
02
Drugs
TG4010
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03353675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353675.